John Edward Adent bought $254K of Neogen (NEOG)
Executed Jan 16 2025, disclosed Jan 16 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Jan 16 2025), the stock returned -11.8% (delay-adjusted); from the execution session (Jan 16 2025), -11.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
John Edward Adent (CEO) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Neogen Corporation (NEOG). Across 1 priced purchase filing, the average 21-session return was -11.8% from execution and -11.8% from disclosure (delay-adjusted; derived). The largest single filing was $254K of NEOG (23,035 sh × $11.03, as filed), executed Jan 16 2025.
Healthcare · Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and in…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→